Cytotoxic effect of the cytosine deaminase gene delivered by the adenovirus vector in murine gastric cancer

2008 ◽  
Vol 2 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Cui Long ◽  
Lin Yanzhen ◽  
Jin Guoxiang ◽  
Yu Dehong ◽  
Tu Yue ◽  
...  
1996 ◽  
Vol 7 (6) ◽  
pp. 713-720 ◽  
Author(s):  
Yonghe Dong ◽  
Patrick Wen ◽  
Yoshinobu Manome ◽  
Michael Parr ◽  
Ari Hirshowitz ◽  
...  

2021 ◽  
Vol 22 (4) ◽  
pp. 1902 ◽  
Author(s):  
Yi-Shu Huang ◽  
Wei-Chuan Hsu ◽  
Chien-Hong Lin ◽  
Sheng-Nan Lo ◽  
Chu-Nian Cheng ◽  
...  

Epidermal growth factor receptor (EGFR) specific therapeutics is of great importance in cancer treatment. Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells. To develop EGFR-specific therapy, 188Re-liposome-Fcy-hEGF was constructed by insertion of Fcy-hEGF fusion protein onto the surface of liposomes encapsulating of 188Re. Western blotting, MALDI-TOF, column size exclusion and flow cytometry were used to confirm the conjugation and bio-activity of 188Re-liposome-Fcy-hEGF. Cell lines with EGFR expression were subjected to treat with 188Re-liposome-Fcy-hEGF/5-FC in the presence of 5-FC. The 188Re-liposome-Fcy-hEGF/5-FC revealed a better cytotoxic effect for cancer cells than the treatment of liposome-Fcy-hEGF/5-FC or 188Re-liposome-Fcy-hEGF alone. The therapeutics has radio- and chemo-toxicity simultaneously and specifically target to EGFR-expression tumor cells, thereby achieving synergistic anticancer activity.


2015 ◽  
Vol 17 (suppl 5) ◽  
pp. v63.2-v63
Author(s):  
Jin Hwa Jung ◽  
Andrew Kim ◽  
Da-Young Chang ◽  
Sung-Soo Kim ◽  
Haeyoung Suh-Kim

2014 ◽  
Vol 55 (3) ◽  
pp. 658-665 ◽  
Author(s):  
Keishi Osakabe ◽  
Ayako Nishizawa-Yokoi ◽  
Namie Ohtsuki ◽  
Yuriko Osakabe ◽  
Seiichi Toki

Sign in / Sign up

Export Citation Format

Share Document